Engineered immune cells take on advanced colon cancer
NCT ID NCT06653010
First seen Jan 25, 2026 · Last updated May 21, 2026 · Updated 13 times
Summary
This early-phase study tests a new type of CAR-T cell therapy (REVO-UWD-01) for people with metastatic colorectal cancer that has spread. The treatment uses specially engineered immune cells to target a protein called GCC found on cancer cells. The main goals are to find a safe dose and check for side effects, while also seeing if the therapy can shrink tumors. About 30 adults aged 18 to 75 with GCC-positive tumors are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
-
Shenzhen Nanshan People's Hospital
Shenzhen, Guangdong, China
Conditions
Explore the condition pages connected to this study.